Background: Tacrolimus (Tac, or FK506), a calcineurin inhibitor (CNI), is the first-line
immunosuppressant which consists of the footstone as immunosuppressive regimens in …

The calcineurin‐inhibitor tacrolimus (Tac) provides an acceptable balance between
prevention of allograft rejection and drug‐related adverse effects, making it the standard of …

The purpose of this study was to determine the intrapatient (within the same patient)
variability of tacrolimus in adherent patients. Daily tacrolimus trough levels were obtained at …

The introduction of tacrolimus in clinical practice has improved patient survival after organ
transplant. However, despite the long use of tacrolimus in clinical practice, the best way to …

Tacrolimus, a calcineurin inhibitor, is a common immunosuppressant prescribed after organ
transplantation and has notable inter‐and intrapatient pharmacokinetic variability. The …

Background Tacrolimus is a key drug in kidney transplantation with a narrow therapeutic
index. However, whether tacrolimus exposure variability affects clinical outcomes and …

Mammalian target of rapamycin (mTOR)-inhibitor-containing immunosuppressive regimens
have been developed as part of calcineurin inhibitor (CNI) minimization/withdrawal …

Cyclosporine, everolimus, and tacrolimus are the cornerstone of immunosuppressive
therapy in renal transplantation. These drugs are characterized by narrow therapeutic …

Tacrolimus is an immunosuppressive calcineurin inhibitor used to prevent rejection in
allogeneic organ transplant recipients, such as kidney, liver, heart or lung. It is metabolized …

Mammalian target of rapamycin, also known as mechanistic target of rapamycin (mTOR) is a
protein kinase that belongs to the PI3K/AKT/mTOR signaling pathway, which is involved in …